Recommendation of the President – Fintepla (fenfluramine)
On 22 July 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 76/2024 on the evaluation of the drug Fintepla (fenfluramine) under the drug program B.154.FM “Treatment of patients with Lennox-Gastaut Syndrome or Dravet Syndrome (ICD-10: G40.4)”